SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.08+0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (8820)7/14/2003 8:15:15 PM
From: Icebrg  Read Replies (1) of 52153
 
>>MEDI has MDX-070 in a Phase I - this is an anti-PSMA antibody that looks interesting. (I think I recall this discussed at the MEDI analyst day webcast, but I'm not sure).>>

A good thing that you hedged yourself. MDX-070 has nothing to do with MEDI. But there are a couple of other players in the field. MDX-070 is being developed as a naked antibody by Medarex. (Who bought the mAb from Northwest Biotherapeutics in a fire-sale, as the latter was about to go under).

Millennium has two versions of anti-PSMA mAbs in the clinic. One radio-labelled and one a toxin-conjugate (IMGN's DM1).

And finally the CYTO/PGNX are developing (or hoping to develop) as they announced today:

- a novel therapeutic prostate cancer vaccine utilizing the PSMA protein and an adjuvant, for which the joint venture announced the initiation of a phase 1 clinical trial in December 2002;

- a therapeutic vaccine that utilizes a viral vector designed to deliver the PSMA gene to immune system cells in order to generate a potent and specific dual-immune response, eliciting both antibodies and killer T cells directed to prostate cancer cells, for which the joint venture anticipates initiating phase 1 clinical studies in the first half of 2004; and

- novel human monoclonal antibodies which bind to PSMA, for which the joint venture expect to begin clinical studies in 2004.

So, there are a lot of activities ongoing in the PSMA sphere. MEDX/MLNM has some kind of crosslicensing agreement, while CYTO/PGNX work on their own.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News